ArticleCancer immunology research2019

Phase I Trial of Autologous CAR T Cells Targeting NKG2D Ligands in Patients with AML/MDS and Multiple Myeloma.

Susanne H Baumeister et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.